Latest Views & News

BREAKING NEWS: Synairgen – Trial "progress", but do you feel lucky?

By Peter Brailey | Sunday 30 August 2020

Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

I wrote about Synairgen (SNGback in July, and in doing so earned the dubious ticker from Tom Winnifrith as a “ramper” and the honour of a Special Bearcast as a response. The ticker amused me greater and I freely admit I agreed with 95% of Tom’s commentary on how to value a drugs company. However I see a “special situation” with this company’s SNG001 potential Covid treatment that may break the normal valuation rule set.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £5.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was